지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한외과학회 Annals of Surgical Treatment and Research Annals of Surgical Treatment and Research Vol.105 No.4
- 발행연도
- 2023.10
- 수록면
- 228 - 236 (9page)
이용수
초록· 키워드
오류제보하기
Purpose: The tablet form of tacrolimus is more convenient for drug ingestion than the capsule form. We examined the efficacy and safety of tacrolimus tablets and a satisfaction survey after formula conversion in liver transplant (LT) recipients.
Methods: This study was an open-label, prospective clinical trial for tacrolimus formula 1:1 conversion from capsule to tablet in 41 adult LT recipients with tacrolimus maintenance therapy of more than 1 month. The primary endpoint was incidence of biopsy-proven acute rejection (BPAR) within 24 weeks. Surveys 1 week before and 4 weeks after formula conversion were conducted for total daily dose of medication, number, scale of discomfort and satisfaction.
Results: The overall incidence of BPAR was 0% and there was no graft loss or patient death. The incidence of adverse effects was 34.1% (n = 14) after formula conversion. The most common severe adverse effect was abnormal liver function test (n = 5): biliary complications (n = 4) and alcoholic recidivism (n = 1). Total daily dose and number of tacrolimus doses were significantly lower after formula conversion (P < 0.05) without changes in trough level. According to survey analysis, there was no significant difference in discomfort and satisfaction scales from capsule to tablet conversion (P < 0.05).
Conclusion: The present study suggests that the new tablet formula can be a useful treatment option to maintain a consistent level of tacrolimus with a lower total daily dose and number in adult LT recipients.
Methods: This study was an open-label, prospective clinical trial for tacrolimus formula 1:1 conversion from capsule to tablet in 41 adult LT recipients with tacrolimus maintenance therapy of more than 1 month. The primary endpoint was incidence of biopsy-proven acute rejection (BPAR) within 24 weeks. Surveys 1 week before and 4 weeks after formula conversion were conducted for total daily dose of medication, number, scale of discomfort and satisfaction.
Results: The overall incidence of BPAR was 0% and there was no graft loss or patient death. The incidence of adverse effects was 34.1% (n = 14) after formula conversion. The most common severe adverse effect was abnormal liver function test (n = 5): biliary complications (n = 4) and alcoholic recidivism (n = 1). Total daily dose and number of tacrolimus doses were significantly lower after formula conversion (P < 0.05) without changes in trough level. According to survey analysis, there was no significant difference in discomfort and satisfaction scales from capsule to tablet conversion (P < 0.05).
Conclusion: The present study suggests that the new tablet formula can be a useful treatment option to maintain a consistent level of tacrolimus with a lower total daily dose and number in adult LT recipients.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Efficacy and safety evaluation after conversion from twice-daily to once-daily tacrolimus in stable liver transplant recipients: A phase 4, open label, single center study
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
Efficacy and safety of a switch from twice- daily tacrolimus to once-daily generic tacrolimus in stable liver transplant patients
Clinical Transplantation and Research
2021 .09
-
1일 2회 투여하는 Tacrolimus에서 1일 1회 투여하는 서방형 Tacrolimus로 전환 시 대응 용량비의 적절성 평가
병원약사회지
2020 .01
-
Risk Factors for the Adverse Events after Conversion from Twice-Daily to Once-Daily Tacrolimus in Stable Liver Transplantation Patients
Journal of Korean Medical Science
2016 .01
-
폐이식 환자에서 tacrolimus와 itraconazole 혹은 voriconazole 병용 시 tacrolimus의 혈중 농도 변화에 미치는 영향
한국임상약학회지
2016 .12
-
The optimal tacrolimus trough level after liver transplantation
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan
Intestinal research
2019 .01
-
Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis
Yonsei Medical Journal
2019 .01
-
Preventive effect of tacrolimus on patients with post- endoscopic retrograde cholangiopancreatography pancreatitis
Clinical Endoscopy
2022 .09
-
신장이식 환자에서 Chemiluminescence Microparticle Immunoassay를 이용한 검사상 Tacrolimus 농도 위증가를 보인 1예
Clinical Transplantation and Research
2016 .01
-
비만환자의 조혈모세포이식 후 체중 적용 기준에 따른 Tacrolimus 초기 농도 비교
병원약사회지
2021 .01
-
Incidence of Topical Tacrolimus Adverse Effects in Chronic Skin Disease
Annals of Dermatology
2019 .01
-
Effectiveness and Safety of Tacrolimus in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-modifying Anti-rheumatic Drugs: The TREASURE Study
대한류마티스학회지
2019 .01
-
Maintenance Therapy of Facial Seborrheic Dermatitis with 0.1% Tacrolimus Ointment
Annals of Dermatology
2015 .01
-
Flat Pattern Peaks of Tacrolimus Absorption and Associated Pharmacogenomic Variants in Kidney Transplantation Recipients
Journal of Korean Medical Science
2022 .02
-
Tacrolimus의 혈중농도 변동성이 간이식 예후에 미치는 영향
한국임상약학회지
2020 .01
-
Cost-Effectiveness and convenience of MyreptⓇ 500mg tablet in recipients after liver transplantation
한국간담췌외과학회 학술대회지
2015 .09
-
Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection
Clinical and Molecular Hepatology
2016 .01
-
신장이식 환자에서 타크로리무스에 의한 발열
대한내과학회지
2019 .06
이 논문의 저자 정보
최근 본 자료
댓글(0)
0